CGBio announced on Wednesday that it is accelerating the expansion of its aesthetic business by exporting the absorbable suture DOOTH to the Japanese market.
DOOTH, an absorbable suture, is set to launch domestically in November 2024.
Traditional absorbable sutures often require tying or tagging to enhance fixation and retention, which could lead to skin indentation or reduced holding power.
DOOTH addresses these issues by being designed to stabilize securely within the body without the need for separate tying.
The company reports that this unique feature has naturally increased recognition among Japanese patients and medical professionals who have experienced DOOTH in Korea.
A CJ Bio spokesperson said Japan’s market demands high standards for product safety and quality, with a strong emphasis on clinical validation and real-world evaluations by medical professionals. The spokesperson added that DOOTH’s technical excellence and competitive edge have been tested in actual clinical settings.
CGBio’s Japanese partner is exploring a phased expansion of DOOTH’s supply in the country.
The company sees this export to Japan as a pivotal moment for DOOTH to establish itself as a global premium product.
Looking ahead, CGBio plans to pursue regulatory approvals in Europe and the United States, backed by forthcoming confirmatory clinical trial results.
Yoo Hyun Seung, CEO of CJ Bio, said the company’s successful entry into the Japanese market, known for its high standards, validates DOOTH’s competitiveness and reflects growing global interest and demand for the product.
